Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 4,31€(+62,03%). Der Median liegt bei 4,31€(+62,03%).
Kaufen | 6 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -4 / 13 |
News
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 100,000 shares of the Company's common stock and rest.» Mehr auf businesswire.com
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with.» Mehr auf businesswire.com
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan C Room The live webcast and subsequent r.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | Sep. 2024 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −21,77 Mio | 38,87% |
EBITDA | −23,64 Mio | 38,92% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 460,38 Mio€ |
Anzahl Aktien | 171,62 Mio |
52 Wochen-Hoch/Tief | 5,46€ - 2,49€ |
Dividenden | Nein |
Beta | 1,02 |
KGV (PE Ratio) | −7,15 |
KGWV (PEG Ratio) | 3,00 |
KBV (PB Ratio) | 2,98 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Savara Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf seltene Atemwegserkrankungen konzentriert. Sein führender Produktkandidat ist Molgramostim, ein inhalativer Granulozyten-Makrophagen-Kolonie-stimulierender Faktor, der sich in der Phase III der Entwicklung zur Behandlung der autoimmunen pulmonalen alveolären Proteinose befindet. Der Hauptsitz des Unternehmens befindet sich in Austin, Texas.
Name | Savara Inc |
CEO | Matthew Pauls J.D., M.B.A. |
Sitz | Austin, tx USA |
Website | |
Industrie | Chemikalien |
Börsengang | 28.04.2017 |
Mitarbeiter | 37 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | SVRA |
Frankfurt | YB4P.F |
Düsseldorf | YB4P.DU |
München | YB4P.MU |
Assets entdecken
Shareholder von Savara Inc investieren auch in folgende Assets